Ario Pharma Commences Efficacy Trial of TRPV1 Inhibitor in Chronic Idiopathic Cough
![](/46/pdcnewsitem/03/34/33/LoN5y8YZc94X4Jg.gif)
Ario Pharma, the biopharmaceutical company developing innovative new treatments for respiratory disease, has commenced a Phase IIa study of its oral TRPV1 antagonist, XEN-D0501, for the treatment and prevention of cough in patients with chronic idiopathic cough (CIC).
Approximately 20 patients will be enrolled into the study, which is being led by Professor Jacky Smith (Principal Investigator), University of Manchester and University Hospital Manchester NHS Foundation Trust, and Dr Lorcan McGarvey, Clinical Senior Lecturer, Queens University and Belfast City Hospital, Belfast. Patients with CIC will be assigned to receive XEN-D0501 or a placebo in a randomised, double-blinded, cross-over study.
XEN-D0501, a potent and selective small molecule inhibitor of TRPV1, has successfully completed multiple Phase I studies and been shown to be safe and well tolerated. The frequency of coughing will be assessed in treatment and placebo groups throughout the study, using validated ambulatory cough monitoring technology developed by Professor Jacky Smith.
Dr John Ford, CEO of Ario Pharma, commented: “Patients with chronic idiopathic cough have a heightened cough reflex which means that their cough is triggered by minor environmental stimuli that would not normally evoke coughing. This neuronal hypersensitivity is mediated through TRPV1 and because XEN-D0501 selectively inhibits TRPV1 it is expected to prevent coughing in this patient group. The study announced today is being conducted in parallel with a second study of XEN-D0501 in patients with cough associated with chronic obstructive pulmonary disease, which is already under way.”
Jacky Smith commented: “It is often not appreciated that chronic cough can be a severe problem, ruining sufferers’ lives. These patients may cough between hundreds and thousands of times per day, and treatment options are extremely limited.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance